- Landmark analysis of OS by response status in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the KEYNOTE-394 studyRen, Zhenggang; Chen, Zhendong; Fang, Weijia; Ou, Shuangyan; Ryoo, Baek-Yeol; Meng, Zhiqiang; Bai, Yuxian; Chen, Xiaoming; Liu, Xiufeng; Xiao, Juxiang; Ho, Gwo Fuang; Mao, Yimin; Wang, Xin; Jieer, Ying; Hao, Chunyi; Shen, Hujia; Lin, Jianxin; Hatogai, Ken; Siegel, Abby B.; Qin, ShukuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)Chen, Jinzhang; Zang, Mengya; Pang, Huajin; Li, Chuanjiang; Zhao, Jianbo; Guo, Yabing; Hou, JinlinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 1
- Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)Zang, M.; Li, Q.; Pang, H.; Hu, X.; Li, R.; Yuan, G.; Li, W.; Guo, Y.; Chen, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
会议论文
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study
73被引21阅读
